Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022)

DNA damage repair in most malignancies with mutation of p53 is more dependent on the G2/M checkpoint. Wee1 kinase is a key regulator of the G2/M checkpoint. If Wee1 is inhibited, it results in cells with unrepaired DNA damage entering mitosis prematurely, leading to mitotic catastrophe and subsequen...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Expert opinion on therapeutic patents Ročník 32; číslo 12; s. 1217 - 1244
Hlavní autoři:	Yan, Jingxue, Zhuang, Lili, Wang, Yong, Jiang, Yiqing, Tu, Zhenlin, Dong, Chao, Chen, Yadong, Zhu, Yong
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis 02.12.2022
Témata:	anticancer cell cycle checkpoint Cell Cycle Checkpoints Cell Cycle Proteins Cell Line, Tumor clinical development Humans inhibitors Neoplasms - drug therapy Neoplasms - genetics Patents as Topic Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Wee1 kinase clinical development inhibitors patent Wee1 kinase anticancer cell cycle checkpoint
ISSN:	1354-3776, 1744-7674, 1744-7674
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!